Abstract:Background: To date, most researchhas focused on the bacterial composition of the human microbiota. In this review, we synopsize recent data on the human mycobiome and cancer, highlighting specific cancer types based on current available evidence, presenting interesting perspectives and limitations of studies and laboratory methodologies. Recent findings: Head and neck cancer carcinoma (HNCC), colorectal carcinoma (CRC) and pancreatic ductal adenocarcinoma (PDA) have been associated with dissimilarities in the composition of mycobiota between cancer cases and non-cancer participants. Overall, fungal dysbiosis with decreased fungal richness and diversity was common in cancer patients; however, a specific mycobiotic signature in HNSCC or CRC has not emerged. Different strains of Candida albicans have been identified among cases with HNCC, whilst Lichtheimia corymbifera, a member of the Mucoraceae family, has been shown to predominate among patients with oral tongue cancer. Virulence factors of Candida spp. include the formation of biofilm and filamentation, and the secretion of toxins and metabolites. CRC patients present a dysregulated ratio of Basidiomycota/Ascomycota. Abundance of Malassezia has been linked to the occurrence and progression of CRC and PDA, particularly in animal models of PDA. Interestingly, Schizophyllum, a component of the oral mycobiome, may exhibit anti-cancer potential. Conclusion: The human mycobiome, per se, along with its interactions with the human bacteriome and the host, may be implicated in the promotion and progression of carcinogenesis. Fungi may be used as diagnostic and prognostic/predictive tools or treatment targets for cancer in the coming years. More large-scale, prospective, multicentric and longitudinal studies with an integrative multi-omics methodology are required to examine the precise contribution of the mycobiome in the etiopathogenesis of cancer, and to delineate whether changes that occur in the mycobiome are causal or consequent of cancer.

Human Mycobiota and Its Role in Cancer Progression, Diagnostics and Therapeutics: A Link Lesser-Known

Fungi and cancer

Unveiling the hidden players: exploring the role of gut mycobiome in cancer development and treatment dynamics

Fungi, host immune response, and tumorigenesis

The Mycobiome: Cancer Pathogenesis, Diagnosis, and Therapy

Mycobiome and Cancer: What Is the Evidence?

The Role of Microbiome in Cancer Cell Stimulation and Therapy

The role of the bacterial microbiome in the treatment of cancer

Fungi and tumors: The role of fungi in tumorigenesis (Review)

Mycobiota and C-Type Lectin Receptors in Cancers: Know thy Neighbors

Unveiling the mycobiota: The fungal frontier of human health

The Human Microbiome and Cancer: a Diagnostic and Therapeutic Perspective

The Colloquy between Microbiota and the Immune System in Colon Cancer: Repercussions on the Cancer Therapy

Bacterial‐fungal interactions and their impact on microbial pathogenesis

An Overview of the Dichotomous Role of Microbiota in Cancer Progression and Management

Fungi in cancer

Pathophysiological and Clinical Potential of Human Microbiome: Microbe-based Therapeutic Insights

Revealing the therapeutic properties of gut microbiota: transforming cancer immunotherapy from basic to clinical approaches

Microbiota in cancer development and treatment

Commensal microbiota in the digestive tract: a review of its roles in carcinogenesis and radiotherapy

The emerging role of oral microbiota in oral cancer initiation, progression and stemness